US Funding Law Could Speed Approval Of Drugs And Biologics Manufactured In Advanced Ways
Executive Summary
FY 2023 appropriations language requires HHS Secretary to designate advanced manufacturing technologies for expedited review, and to follow up with advice and meetings that could help move things along.
You may also be interested in...
US FDA Stance Against Biologics Outsourcing Draws Fire From Cell & Gene Therapy Sector
Groups representing contract manufacturers and cell and gene therapy developers criticized agency’s actions forcing biologics sponsors to grapple with chemistry, manufacturing and controls challenges instead of relying on contract manufacturers’ proprietary technologies.
2023 US FDA Drug Quality Guidance Expected To Include 20-Year CTD Update, Much More
A revision of the ICH Common Technical Document expected this year will set the global stage for eventual “structured” quality submissions. Meanwhile, the FDA plans to complete work on ICH impurities guidance and advanced manufacturing technology guidance.
How US FDA Must Designate Manufacturing Platforms To Help Speed Approvals
Initial product approvals will kick off a process that an FY23 spending bill provision establishes for the pharmaceutical industry to build on prior knowledge from manufacturing platform technologies. But the FDA can only designate platforms that really will expedite the development and review of new drugs and biologics.